The evidence for pharmaceutical interventions in any chronic disease comes mostly from secondary care or tertiary care in highly selected patients for research. However, in many countries, chronic diseases are primarily treated in primary care. Since patients with chronic diseases in secondary care are often referred for their complexity, we know little about the large group of ordinary patients and their reaction on treatment in real life. This means that there is a lack of evidence regarding the treatment of the ordinary patient in primary care. The lack of real world evidence is acknowledged, but actual conduction of real world studies in primary care can be challenging. With lack of time and experience for the administrative burden of trials, GP’s are hesitant to participate. Since GP practices are small, sponsors and CRO’s are hesitant to use GP practices, as multiple GP practices have to be approached to reach the required sample size. This is where GPRI comes in. GPRI facilitates GP practices, lowering the threshold for study participation, and ensuring the unmet need is solved.